Comparative Pharmacology
Head-to-head clinical analysis: HYDERGINE versus HYDERGINE LC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDERGINE versus HYDERGINE LC.
HYDERGINE vs HYDERGINE LC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ergoloid mesylates (Hydergine) are a mixture of dihydrogenated ergot alkaloids that act as non-selective dopamine D1 and D2 receptor agonists and serotonin receptor antagonists. They enhance cerebral blood flow and neuronal metabolism, and modulate neurotransmitter activity.
Ergoloid mesylates (dihydroergotoxine) act as a partial agonist/antagonist at dopamine (D1, D2), serotonin (5-HT1, 5-HT2), and alpha-adrenergic receptors. They enhance cerebral metabolism and increase blood flow via vasodilation and neuroprotection.
1-2 mg orally three times daily.
Oral, 1 mg three times daily. Titrate up to 2 mg three times daily if needed.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours; clinically, steady-state is achieved within 3-5 days.
Terminal elimination half-life: 12–15 hours. Clinical context: steady-state achieved in 2–3 days; allows once-daily dosing.
Primarily fecal (80%) via biliary excretion; renal excretion accounts for <10% of unchanged drug.
Renal (80% as metabolites, <1% unchanged); biliary/fecal (20%).
Category C
Category C
Ergot Alkaloid
Ergot Alkaloid